Literature DB >> 28509814

Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.

Janet S Carpenter1, Giorgos Bakoyannis, Julie L Otte, Chen X Chen, Kevin L Rand, Nancy Woods, Katherine Newton, Hadine Joffe, JoAnn E Manson, Ellen W Freeman, Katherine A Guthrie.   

Abstract

OBJECTIVES: To conduct psychometric analyses to condense the Hot Flash-Related Daily Interference Scale (HFRDIS) into a shorter form termed the Hot Flash Interference (HFI) scale; evaluate cut-points for both scales; and establish minimally important differences (MIDs) for both scales.
METHODS: We analyzed baseline and postrandomization patient-reported data pooled across three randomized trials aimed at reducing vasomotor symptoms (VMS) in 899 midlife women. Trials were conducted across five MsFLASH clinical sites between July 2009 and October 2012. We eliminated HFRDIS items based on experts' content validity ratings and confirmatory factor analysis, and evaluated cut-points and established MIDs by mapping HFRDIS and HFI to other measures.
RESULTS: The three-item HFI (interference with sleep, mood, and concentration) demonstrated strong internal consistency (alphas of 0.830 and 0.856), showed good fit to the unidimensional "hot flash interference factor," and strong convergent validity with HFRDIS scores, diary VMS, and menopausal quality of life. For both scales, cut-points of mild (0-3.9), moderate (4-6.9), and severe (7-10) interference were associated with increasing diary VMS ratings, sleep, and anxiety. The average MID was 1.66 for the HFRDIS and 2.34 for the HFI.
CONCLUSIONS: The HFI is a brief assessment of VMS interference and will be useful in busy clinics to standardize VMS assessment or in research studies where response burden may be an issue. The scale cut-points and MIDs should prove useful in targeting those most in need of treatment, monitoring treatment response, and interpreting existing and future research findings.

Entities:  

Mesh:

Year:  2017        PMID: 28509814      PMCID: PMC6002749          DOI: 10.1097/GME.0000000000000871

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   3.310


  48 in total

1.  Symptom clusters during the late reproductive stage through the early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Lori A Cray; Nancy Fugate Woods; Jerald R Herting; Ellen Sullivan Mitchell
Journal:  Menopause       Date:  2012-08       Impact factor: 2.953

2.  Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.

Authors:  Janet S Carpenter; Anna Maria Storniolo; Shelley Johns; Patrick O Monahan; Faouzi Azzouz; Julie L Elam; Cynthia S Johnson; Richard C Shelton
Journal:  Oncologist       Date:  2007-01

3.  Symptom interference with work and relationships during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell
Journal:  Menopause       Date:  2011-06       Impact factor: 2.953

4.  Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

Authors:  Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 5.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

6.  A menopause-specific quality of life questionnaire: development and psychometric properties.

Authors:  J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn
Journal:  Maturitas       Date:  1996-07       Impact factor: 4.342

7.  Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases.

Authors:  R L Daut; C S Cleeland; R C Flanery
Journal:  Pain       Date:  1983-10       Impact factor: 6.961

8.  MsFLASH participants' priorities for alleviating menopausal symptoms.

Authors:  J S Carpenter; N F Woods; J L Otte; K A Guthrie; C Hohensee; K M Newton; H Joffe; L Cohen; B Sternfeld; R J Lau; S D Reed; A Z LaCroix
Journal:  Climacteric       Date:  2015-10-30       Impact factor: 3.024

9.  Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Authors:  Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix
Journal:  JAMA       Date:  2011-01-19       Impact factor: 157.335

10.  Symptom clusters among MsFLASH clinical trial participants.

Authors:  Nancy Fugate Woods; Chancellor Hohensee; Janet S Carpenter; Lee Cohen; Kristine Ensrud; Ellen W Freeman; Katherine A Guthrie; Hadine Joffe; Andrea Z LaCroix; Julie L Otte
Journal:  Menopause       Date:  2016-02       Impact factor: 3.310

View more
  4 in total

1.  Development and Testing of the Dysmenorrhea Symptom Interference (DSI) Scale.

Authors:  Chen X Chen; Tabitha Murphy; Susan Ofner; Lilian Yahng; Peter Krombach; Michelle LaPradd; Giorgos Bakoyannis; Janet S Carpenter
Journal:  West J Nurs Res       Date:  2020-07-17       Impact factor: 1.967

Review 2.  Assessment of the climacteric syndrome: a narrative review.

Authors:  Marina Sourouni; Martina Zangger; Livia Honermann; Dolores Foth; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2021-07-06       Impact factor: 2.344

3.  Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.

Authors:  S Iliodromiti; W Wang; M A Lumsden; M S Hunter; R Bell; G Mishra; M Hickey
Journal:  BJOG       Date:  2019-11-13       Impact factor: 6.531

4.  Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

Authors:  Nanette Santoro; Arthur Waldbaum; Samuel Lederman; Robin Kroll; Graeme L Fraser; Christopher Lademacher; Laurence Skillern; James Young; Steven Ramael
Journal:  Menopause       Date:  2020-12       Impact factor: 3.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.